Cell Lysis Market, by Product Type (Instruments and Consumables), by Cell Type (Mammalian Cells, Microbial Cells, and Other Cells), by End User (Academic and Research Labs and Pharmaceutical and Biotechnology Companies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Published In : Jul 2022

Code : CMI741

Pages :152

Formats :

Excel and PDF

Industry : Biotechnology

Cell Lysis MarketSize and Trends

Global cell lysis market is estimated to be valued at US$ 3,781.33 million in 2022 and is expected to exhibit a CAGR of 8.6% during the forecast period (2022-2030).

Figure 1.Global Cell Lysis Market Share (%), by Product Type, 2022

Increasing research and development in the field of proteomics and genomics are expected to drive growth of the cell lysis market

Increasing research and development in the field of proteomics and genomics and high prevalence of infectious diseases and cancer are the major factors driving growth of the cell lysis market. Advancements and approvals for cell-based therapies are expected to support growth of cell lysis market.

In May 2022, Novartis AG, a global healthcare company, announced that the US Food and Drug Administration (FDA) had granted accelerated approval for Kymriah (tisagenlecleucel) for the treatment of adult patients with relapsed or refractory (r/r) follicular lymphoma (FL) after two or more lines of systemic therapy. Kymriah is now FDA approved in three indications and remains the only CAR-T cell therapy approved in both adult and pediatric settings.

High prevalence of infectious diseases and cancer are expected to drive market growth during the forecast period.

Rising prevalence of cancer is expected to drive market growth over the forecast period. Breast cancer is the second most common type of cancer in the U.S., after skin cancer. Breast cancer can occur both, in men and women. However, it is mostly found among females and the male occurrence of breast cancer is very rare. For instance, according to the data provided by Breastcancer.org, in March 2022, an estimated 287,850 new cases of invasive breast cancer are expected to be diagnosed in women in the U.S., along with 51,400 new cases of non-invasive (in situ) breast cancer in 2022.